Trials / Active Not Recruiting
Active Not RecruitingNCT06376084
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Osimertinib With Chemotherapy as First-line Therapy for Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-Small Cell Lung Cancer (NSCLC): A Multicentre, Observational Study (FOREFRONT)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 532 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS .
Detailed description
The objectives of this study are to assess the effectiveness and safety of Osimertinib combined with chemotherapy in a real-world setting in patients with locally advanced or metastatic, EGFR mutation-positive NSCLC.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
Timeline
- Start date
- 2024-07-23
- Primary completion
- 2028-02-28
- Completion
- 2028-02-28
- First posted
- 2024-04-19
- Last updated
- 2026-01-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06376084. Inclusion in this directory is not an endorsement.